Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Date:8/8/2008

rite-down of our investment in Napo. This investment, which was funded by a milestone payment from Napo, was recorded as part of our agreement with Napo in 2007.

For the six months ended June 30, 2008, revenues totaled $5.0 million, up from $3.9 million in the first six months of 2007. Consistent with second quarter results, the increase was primarily attributable to a $3.0 million improvement in cost recovery from our EAP to treat patients with ALS in Italy. This was partially offset by the absence of license income from Napo and the revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and Tercica Inc. entered into in 2007.

The net loss for the six months ended June 30, 2008 was $9.5 million, or $0.08 per share, compared to $12.8 million, or $0.12 per share, for first six months of 2007. Year-over-year, R&D Expenses increased to $10.8 million for the first half of 2008, from $9.8 million, reflecting an increase in clinical trial activity for our FOB and IPLEX(TM) programs. SG&A Expenses fell to $3.0 million for the first half of 2008 from $6.5 million a year earlier due to the elimination of litigation expenses following the March 2007 settlement and the removal of commercial expenses associated with our business restructuring plan. The $446,000 loss on investments represents the write down on the Napo investment during the first half of 2008.

Interest income for the first half of 2008 was $375,000 and was a reduction from the $525,000 earned in the same period of 2007 due to the combination of a lower interest rate environment and a lower average cash balance. Interest expense increased to $682,000 in the most recent six month period from $306,000 during the corresponding period of 2007. The increase was due to an increase in the debt discount amortization resulting from the quarterly payment of our 2005 convertible notes, which began in March 2008. '/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... , May 4 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ... studies with ANAVEX 2-73, the company,s lead compound for the treatment ... , , ... class of drugs that target mitochondrial dysfunction thought to be caused ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
... , , , ... EDMONTON, AB , May 3 /PRNewswire-FirstCall/ - ... strategy. The Company,s new strategy will encompass becoming a full ... invest in and advise companies on strategy, financing, mergers & ...
Cached Biology Technology:Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
(Date:4/16/2014)... Biosciences Division of Lawrence Berkeley National Laboratory (Berkeley Lab) ... authority on the evolutionary design principles of cellular networks ... biology, has been named one of six recipients of ... Secretary Ernest Moniz. The E.O. Lawrence Award, the Department ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3Gate for bacterial toxins found 2
... July 6 Delays in cargo screening significantly extend ... be shortened with foolproof and rapid screening and detection ... smuggling augment the need for efficient access control systems ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , New analysis from ...
... , WASHINGTON, July 7 Eight supply chain professionals were ... organization,s Board of Directors, joining the seven existing members of SCC,s board. ... through June 30, 2012, are as follows: , , , ... CTO, Manufacturing & Distribution Industries, Hewlett Packard , ...
... , , LONDON, July 10 IBM (NYSE: ... executive agency of the UK Home Office, have signed a seven-year agreement ... upgrade to biometric passports and enhance the security of the UK border. ... (UKBA) Immigration and Asylum Fingerprint System (IAFS) which holds biometrics collected from ...
Cached Biology News:Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 3UK Identity and Passport Service and IBM Sign 7-year National Biometric Identity Service (NBIS) Contract 2
... culture or fermentation is the ability to ... make rapid adjustments in response to changes ... provide immediate analysis of key nutrients, metabolites, ... media. BioProfile analyzers are fully automated, multi-test ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... sequence corresponds to residues 115-133 of rat SAP97. The sequence ... L - P - S - E - R - I ... N - E - V - L - G - P ... conjugation and is not a part of the native rat SAP97 ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: